Safety Considerations of Fluoroquinolones in the Elderly (original) (raw)
Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998; 10: 255–7 ArticlePubMedCAS Google Scholar
Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20(4): 289–302 ArticlePubMedCAS Google Scholar
Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093–9 PubMedCAS Google Scholar
Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007; 120: 893–900 ArticlePubMed Google Scholar
Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations [published erratum appears in Curr Med Res Opin 2007; 23 (9): 303]. Curr Med Res Opin 2007; 23(6): 1403–13 ArticlePubMedCAS Google Scholar
Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections [corrected and republished in J Antimicrob Chemother 2002; 50 (1): 151-4]. J Antimicrob Chemother 2002; 49(5): 709–12 ArticlePubMedCAS Google Scholar
Gomolin IH, Siami PF, Reuning-Scherer J, et al., and Oral Suspension Study Group. Efficacy and safety of ciprofloxacin oral suspension versus trimethoprim/sulfamethoxazole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc 2001; 49: 1606–13 ArticlePubMedCAS Google Scholar
Noreddin AM, Hoban DJ, Zhanel GG. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26(2): 120–5 ArticlePubMedCAS Google Scholar
Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28(5): 443–52 ArticlePubMedCAS Google Scholar
Ball P, File TM, Twynholm M, et al. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001; 18(1): 19–27 ArticlePubMedCAS Google Scholar
Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73–81 ArticlePubMedCAS Google Scholar
Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or=65 years with community-acquired pneumonia. Clin Ther 2005; 27(8): 1251–9 ArticlePubMedCAS Google Scholar
Nicholson SC, High KP, Gothelf S, et al. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis 2002; 44(1): 109–16 ArticlePubMedCAS Google Scholar
Keam SJ, Croom KF, Keating GM. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. Drugs 2005; 65(5): 695–724 ArticlePubMedCAS Google Scholar
Graber H, Ludwig E, Arr M, et al. Difference in multiple-dose pharmacokinetics of ofloxacin in young and aged patients [abstract no. 94]. International Symposium on New Quinolones; 1986 Jul 17-19; Geneva
Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562–5 PubMedCAS Google Scholar
Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62(1): 169–207 ArticlePubMedCAS Google Scholar
Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59(1): 115–39 ArticlePubMedCAS Google Scholar
Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4(2): 145–73 ArticlePubMedCAS Google Scholar
van Zanten AR, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23(3): 422–30 ArticlePubMed Google Scholar
Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25(5): 717–40 ArticlePubMedCAS Google Scholar
Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs 2008; 17(5): 779–86 ArticlePubMedCAS Google Scholar
Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Resp Dis 1999; 20 Suppl.: S70–6 Google Scholar
Springsklee M, Reiter C, Meyer JM. Safety and tolerability of moxifloxacin (MXF) [abstract no. 260]. Antiinfect Drugs Chemother 2000; 17(1): 90 Google Scholar
Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26(7): 940–50 ArticlePubMedCAS Google Scholar
Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58Suppl. 2: 65–70 ArticlePubMedCAS Google Scholar
Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81–5 ArticlePubMedCAS Google Scholar
Ljungberg B, Nilsson-Ehle I, Edlund C, et al. Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. Scand J Infect Dis 1990; 22: 205–8 ArticlePubMedCAS Google Scholar
Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002; 346(5): 334–9 ArticlePubMed Google Scholar
Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Inf Dis 2005; 41(9): 1254–60 Article Google Scholar
Rao GG, Rao CSM, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with β-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697–701 ArticleCAS Google Scholar
Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacother 2006; 26(1): 61–7 Article Google Scholar
Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51(6): 1339–50 ArticlePubMedCAS Google Scholar
Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009; 63(2): 238–42 ArticlePubMedCAS Google Scholar
Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 41(11): 1859–66 ArticlePubMed Google Scholar
Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269–77 ArticlePubMedCAS Google Scholar
Kawahara K, Kawahara M, Goto T, et al. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy 1991; 39: 149–57 Google Scholar
Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother 1994; 38: 1356–62 ArticlePubMedCAS Google Scholar
Leone M, Sampol-Manos E, Santelli D, et al. Brain tissue penetration of ciprofloxacin following a single intravenous dose. J Antimicrob Chemother 2002; 50(4): 607–9 ArticlePubMedCAS Google Scholar
Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194–8 ArticlePubMedCAS Google Scholar
Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environment Health 1995; 45: 1–45 ArticleCAS Google Scholar
Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41: S144–57 ArticlePubMedCAS Google Scholar
Schmuck G, Schürmann A, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831–6 PubMedCAS Google Scholar
Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7(6): 639–51 ArticlePubMedCAS Google Scholar
Brouwers EE, Söhne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29: 59–63 ArticlePubMedCAS Google Scholar
Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352–64 ArticlePubMedCAS Google Scholar
Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32(5): 359–78 ArticlePubMed Google Scholar
Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421–9 ArticlePubMedCAS Google Scholar
Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593–6 ArticlePubMedCAS Google Scholar
Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296(3): 806–10 PubMedCAS Google Scholar
Kang J, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122–6 PubMedCAS Google Scholar
Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Todays Therapeutic Trends 2000; 18: 205–23 Google Scholar
Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT-interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861–3 ArticlePubMed Google Scholar
Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663–8 ArticlePubMed Google Scholar
Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75(3): 242–7 ArticlePubMedCAS Google Scholar
Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128: 3398–406 ArticlePubMedCAS Google Scholar
Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28(10): 1162–4 PubMedCAS Google Scholar
Ho CC, Chen YC, Hu FC, et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009; 48(11): 1526–33 ArticlePubMedCAS Google Scholar
Lode HM, Schmidt-Ionas M. Moxifloxacin: update and perspectives after 8 years of usage. Exp Rev Resp Med 2008; 2: 443–53 ArticleCAS Google Scholar
Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008; 8(2): 83–5 ArticlePubMed Google Scholar
Grayson ML. Synthetic antibacterial and antiparasitic drugs. In: Kucers A, Crowe SM, Grayson ML, et al., editors. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford: Butterworth, Heinemann, 1997: 981–1060 Google Scholar
Famularo G, De Simone C. Nephrotoxicity and purpura associated with levofloxacin. Ann Pharmacother 2002; 36(9): 1380–2 ArticlePubMed Google Scholar
Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis [abstract]. Am J Kidney Dis 2003; 41(2): E7 ArticlePubMed Google Scholar
Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50(2): 330–5 ArticlePubMed Google Scholar
Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urology 2000; 164: 438 ArticleCAS Google Scholar
Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33(3): 194–200 ArticlePubMedCAS Google Scholar
Förster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474–81 ArticlePubMed Google Scholar
Förster C, Schwabe R, Lozo E, et al. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Arch Toxicol 1997; 72: 26–32 ArticlePubMed Google Scholar
Stahlmann R, Förster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013–8 ArticlePubMedCAS Google Scholar
Lozo E, Riecke K, Schwabe R, et al. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 2002; 46: 1755–9 ArticlePubMedCAS Google Scholar
Pfister K, Mazur D, Vormann J, et al. Diminished ciprofloxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob Agents Chemother 2007; 51(3): 1022–7 ArticlePubMedCAS Google Scholar
Van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45: 235–9 ArticlePubMed Google Scholar
Damuth E, Heidelbaugh J, Malani PN, et al. An elderly patient with fluoroquinolone-associated Achilles tendinitis. Am J Geriatr Pharmacother 2008; 6(5): 264–8 ArticlePubMed Google Scholar
Parmar C, Meda KP. Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot Ankle Int 2007; 28: 1287–9 ArticlePubMed Google Scholar
Vyas H, Krishnaswamy G. Images in clinical medicine. Quinolone-associated rupture of the Achilles’ tendon [letter]. N Engl J Med 2007; 357(20): 2067 ArticlePubMedCAS Google Scholar
Kahn MF, Hayem G. Tendons and fluoroquinolones: unresolved issues. Rev Rhum Engl Ed 1997; 64: 437–9 PubMedCAS Google Scholar
Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie 1996; 51: 419–20 PubMedCAS Google Scholar
Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433–7 ArticlePubMed Google Scholar
Simonin M-A, Gegout-Pottie P, Minn A, et al. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000; 44: 867–72 ArticlePubMedCAS Google Scholar
Shakibaei M, Pfister K, Schwabe R, et al. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 2000; 44: 261–6 ArticlePubMedCAS Google Scholar
Shakibaei M, Stahlmann R. Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97–102 ArticlePubMedCAS Google Scholar
Shakibaei M, Baumann-Wilschke I, Stahlmann R. Quinolone-induced changes in Achilles tendons from rats persist for several months [poster no. P130]. J Antimicrob Chemother 2001;47Suppl. S1: 49 Google Scholar
Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497(1): 111–7 ArticlePubMedCAS Google Scholar
Ambrose PG, Bhavnani SM, Owens Jr RC. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17(3): 529–43 ArticlePubMed Google Scholar
Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52(3): 435–40 ArticlePubMedCAS Google Scholar
Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354(13): 1352–61 ArticlePubMedCAS Google Scholar